Explore
Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Read More
Trendline
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Read More
Trendline
Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026
Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026
Read More
Trendline
FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients
FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients
Read More
Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark
Read More
Trendline
FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data
FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data
Read More
Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Read More
Trendline
Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks
Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks
Read More
Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Read More
Trendline
Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer
Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer
Read More
Trendline
Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline
Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline
Read More